摘要
目的评价替考拉宁治疗革兰阳性球菌所致呼吸机相关性肺炎的疗效与安全性。方法对35例应用替考拉宁治疗的革兰阳性球菌所致呼吸机相关性肺炎的患者进行治疗前后的临床症状、体征、临床疗效、细菌清除情况以及不良反应的分析,并将临床分离菌进行替考拉宁体外药敏试验。结果替考拉宁治疗革兰阳性球菌所致呼吸机相关性肺炎的临床总有效率为82.85%,细菌清除率为85.71%,进步及无效患者均为重症感染及慢性阻塞性肺疾病患者,不良反应发生率2.85%;替考拉宁对痰培养所得的35株耐甲氧西林金黄色葡萄球菌、耐甲氧西林表皮葡萄球菌、粪肠球菌、屎肠球菌和溶血葡萄球菌均敏感。结论替考拉宁治疗革兰阳性球菌所致呼吸相关性肺炎疗效显著,且安全可靠。
OBJECTIVE To evaluaten the efficacy and safety of teicoplanin treatment in patients with ventilatorassociated pneumonia （VAP） of Gram-positive bacterial infections. METHODS Thirty-five patients with VAP of Gram-positive bacterial infections were treated with teicoplanin. The clinical symptom, therapeutic effect, clearance rate of pathogens,and side effects were analyzed. In vitro sensitivity test to lycopeptide antibiotics was assayed in 35 strains of pathogens. RESULTS The clinical effective rate of teieoplanin was 82.85 %. The clearance rate accounted for 85.71%. The adverse reaction rate was 2.85%. The patients with the grade of progress and inefficacy were someone with severe infection or chronic obstructive pulmonary disease. In vitro, the sensitivity test to teicoplanin of 35 strains of pathogens were 100.00%. CONCLUSIONS It is high efficacy and safety to use reasonably teicoplanin in the patients with VAP of Gram-positive bacterial infections.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2010年第7期1001-1002,共2页
Chinese Journal of Nosocomiology
关键词
替考拉宁
呼吸机相关性肺炎
革兰阳性球菌
Teicoplanin
Ventilator-associated pneumonia
Gram-positive bacterial
